U2Bio Co (XKRX:221800) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Debt-to-Equity?

U2Bio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩260 Mil. U2Bio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩192 Mil. U2Bio Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩37,991 Mil. U2Bio Co's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for U2Bio Co's Debt-to-Equity or its related term are showing as below:

XKRX:221800' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.36 Max: 1.43
Current: 0.01

During the past 9 years, the highest Debt-to-Equity Ratio of U2Bio Co was 1.43. The lowest was 0.01. And the median was 0.36.

XKRX:221800's Debt-to-Equity is ranked better than
99.48% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs XKRX:221800: 0.01

U2Bio Co Debt-to-Equity Historical Data

The historical data trend for U2Bio Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co Debt-to-Equity Chart

U2Bio Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.08

1.43

0.09

0.02

0.01

U2Bio Co Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	N/A	0.02	0.01	0.01

Competitive Comparison of U2Bio Co's Debt-to-Equity

For the Diagnostics & Research subindustry, U2Bio Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U2Bio Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where U2Bio Co's Debt-to-Equity falls into.

U2Bio Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

U2Bio Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(260.307	+	191.958)	/	37991.41
	=	0.01

U2Bio Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(260.307	+	191.958)	/	37991.41
	=	0.01

U2Bio Co (XKRX:221800) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

U2Bio Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of U2Bio Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

U2Bio Co (XKRX:221800) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Basement 1, 68 Gumaro Songpagu, Seoul, KOR

Website

http://www.u2bio.co.kr

U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co (XKRX:221800) Headlines

No Headlines